Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors

被引：0
|
作者：
Zhou, Qing
Wu, Yi Long
Yu, Xiyong
Yang, Jinji
Wen, Limin
Sai, Yang
Mu, Hua
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Gen Hosp, Med Res Ctr, Guangzhou, Guangdong, Peoples R China
[4] Hutchison MediPharma, Shanghai, Peoples R China
[5] Hutchison Medi Pharma, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19042
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
    Mross, Klaus
    Richly, Heike
    Frost, Annette
    Scharr, Dirk
    Nokay, Bahar
    Graeser, Ralph
    Lee, Chooi
    Hilbert, James
    Goeldner, Rainer-George
    Fietz, Oliver
    Scheulen, Max E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 405 - 417
  • [42] Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors
    Niwakawa, Masashi
    Yamaguchi, Raizo
    Onozawa, Yusuke
    Yasui, Hirofumi
    Taku, Keisei
    Naito, Tateaki
    Akinaga, Shiro
    Boku, Narikazu
    Yamamoto, Nobuyuki
    CANCER SCIENCE, 2013, 104 (08) : 1039 - 1044
  • [43] A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
    Wagner, Andrew J.
    Messersmith, Wells A.
    Shaik, M. Naveed
    Li, Sherry
    Zheng, Xianxian
    McLachlan, Karen R.
    Cesari, Rossano
    Courtney, Rachel
    Levin, Wendy J.
    El-Khoueiry, Anthony B.
    CLINICAL CANCER RESEARCH, 2015, 21 (05) : 1044 - 1051
  • [44] A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
    Jian Zhang
    Junning Cao
    Jin Li
    Yifan Zhang
    Zhiyu Chen
    Wei Peng
    Si Sun
    Naiqing Zhao
    Jiachen Wang
    Dafang Zhong
    Xiaofang Zhang
    Jing Zhang
    Journal of Hematology & Oncology, 7
  • [45] A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
    Zhang, Jian
    Cao, Junning
    Li, Jin
    Zhang, Yifan
    Chen, Zhiyu
    Peng, Wei
    Sun, Si
    Zhao, Naiqing
    Wang, Jiachen
    Zhong, Dafang
    Zhang, Xiaofang
    Zhang, Jing
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [46] A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
    Mojun Zhu
    Julian R. Molina
    Grace K. Dy
    Gary A. Croghan
    Yingwei Qi
    James Glockner
    Lorelei J. Hanson
    Michelle M. Roos
    Angelina D. Tan
    Alex A. Adjei
    Investigational New Drugs, 2020, 38 : 1755 - 1762
  • [47] A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
    Zhu, Mojun
    Molina, Julian R.
    Dy, Grace K.
    Croghan, Gary A.
    Qi, Yingwei
    Glockner, James
    Hanson, Lorelei J.
    Roos, Michelle M.
    Tan, Angelina D.
    Adjei, Alex A.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1755 - 1762
  • [48] A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers
    Aflah Roohullah
    Adam Cooper
    Anna J. Lomax
    Jennifer Aung
    Alan Barge
    Lilian Chow
    Mark McHale
    Jayesh Desai
    James R. Whittle
    Ben Tran
    Paul de Souza
    Lisa G. Horvath
    Investigational New Drugs, 2018, 36 : 886 - 894
  • [49] Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
    Yap, Timothy A.
    Krebs, Matthew G.
    Postel-Vinay, Sophie
    El-Khouiery, Anthony
    Soria, Jean-Charles
    Lopez, Juanita
    Berges, Alienor
    Cheung, S. Y. Amy
    Irurzun-Arana, Itziar
    Goldwin, Andrew
    Felicetti, Brunella
    Jones, Gemma N.
    Lau, Alan
    Frewer, Paul
    Pierce, Andrew J.
    Clack, Glen
    Stephens, Christine
    Smith, Simon A.
    Dean, Emma
    Hollingsworth, Simon J.
    CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5213 - 5224
  • [50] A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers
    Roohullah, Aflah
    Cooper, Adam
    Lomax, Anna J.
    Aung, Jennifer
    Barge, Alan
    Chow, Lilian
    McHale, Mark
    Desai, Jayesh
    Whittle, James R.
    Tran, Ben
    de Souza, Paul
    Horvath, Lisa G.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 886 - 894
12345